BioSpace News Archive

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, announced its provisional financial calendar for 2023.

Casana, the leader in smart toilet heart health monitoring, announced today a catalyst year of advancement while pursuing FDA clearance for the firm’s first product, The Heart Seat™.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”) yesterday commemorated the third anniversary of the completion of the principal design work of a Co-Primers™ PCR test for what was, on January 23, 2020, still known as 2019-nCoV, or the novel coronavirus.

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the release of its white paper, “Clinical Study of Novel Skin Biomarker Test for Alzheimer’s Disease Gains Vigorous Physician Support in Long-Sought Early Detection Breakthrough.”

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares of common stock at a public offering price of $5.00 per share for gross proceeds of $7,000,000, before deducting underwriting discounts and estimated offering expenses.

Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer

Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.

Precigen, Inc. announced it has commenced an underwritten public offering of $75.0 million of its common stock.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced the closing of its underwritten public offering of 7,986,111 shares of its common stock.

SenesTech, Inc. announced announced the management team will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.